CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 104 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05772832
NCT05772832N/ACompleted
CompareCT.gov

COMPARISON OF DEXMEDETOMIDINE AND REMIFENTANIL FOR POSTOPERATIVE PAIN IN TRANSPHENOIDAL Pituitary SURGERY

Kocaeli University·observational·Posted Mar 16, 2023·Updated Aug 27, 2025

In Brief

An observational study evaluating Dexmedetomidine and Remifentanyl for Postoperative Pain. Completed, enrolled 104 participants across 1 site.

Detailed Summary

In patients with pituitary adenoma scheduled for endoscopic transsphenoidal pituitary surgery, it was aimed to compare the efficacy of postoperative pain relief of a selective α-2 agonist "Dexmedetomidine" and the rapid and short-acting opioid "Remifentanil" using the "Numerical Rating Scale" (NRS) administered alongside propofol in perioperative maintenance anesthesia. .

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Pain
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMar 16, 2023
Enrollment StartNov 17, 2021
Primary CompletionDec 14, 2022
Study CompletionFeb 22, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.3 years ago

Interventions

Dexmedetomidinedrug

Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery

Remifentanyldrug

Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery